---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-270796"
form_type: "8-K/A"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:48:08.433888+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coherus files Surface Oncology audited financials: $63.6M net loss in 2022, going concern noted

## Summary
- Surface Oncology reported net loss of $63.6M for 2022 on $30M revenue; accumulated deficit reached $204.3M.
- Auditor raised substantial doubt about Surface's ability to continue as a going concern due to operating losses, debt repayment, and lease termination.
- For 2020, Surface had net income of $59.3M and revenue of $126.2M from GSK license, but losses resumed thereafter.
- Pro forma combined financial statements as of June 30, 2023 reflect the merger with Coherus, completed September 8, 2023.
- Surface paused internal clinical development of SRF617 and reduced workforce by ~20% in Q4 2022, incurring $4M restructuring charge.

## SEC filing metadata
- accession: 0001193125-23-270796
- form_type: 8-K/A
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000119312523270796/0001193125-23-270796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000119312523270796/d574677d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-270796
- JSON: https://secwatch.observer/filing/0001193125-23-270796.json
- Plain text: https://secwatch.observer/filing/0001193125-23-270796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.